“Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials”. 2024. SKIN The Journal of Cutaneous Medicine 8 (4): s407. https://doi.org/10.25251/skin.8.supp.407.